Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01706939 · ClinicalTrials.gov registry record · Phase 3
The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer
A Phase 3 study of Squamous Cell Carcinomas, sponsored by Icahn School of Medicine at Mount Sinai.
- Active
- Registry status
- Phase 3
- Development phase
- 23
- Enrollment target
- 1
- Study location
NCT01706939 is a Phase 3 study of Squamous Cell Carcinomas that is active but no longer recruiting, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 23 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01706939, a Phase 3 study of Squamous Cell Carcinomas, is active but no longer recruiting, sponsored by Icahn School of Medicine at Mount Sinai.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 23 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial aims to directly compare a reduced radiation dose to the standard of care in HPVOPC for non-inferiority, thus allowing for direct comparison of outcomes between the two groups. The study hypothesis is that LRC and PFS at 3 years for reduced dose CRT are non-inferior to standard dose CRT.
Conditions Studied
Interventions
- DRUG Carboplatin
- RADIATION Standard Dose Radiation
- RADIATION Reduced Dose Radiation
Study Locations (1)
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2012-09-01 |
| Est. Completion | 2035-05-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01706939
The ClinicalTrials.gov registry entry for NCT01706939 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Squamous Cell Carcinomas appearing as the primary indexed condition, and to 3 interventions - of which Carboplatin is the first listed.
NCT01706939 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01706939 about?
NCT01706939 is a clinical study titled "The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer". This trial aims to directly compare a reduced radiation dose to the standard of care in HPVOPC for non-inferiority, thus allowing for direct comparison of outcomes between the two groups. The study hypothesis is that LRC and PFS at 3 years for reduced dose CRT are non-inferior to standard dose CRT.
What is the current status of trial NCT01706939?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 23 participants. The study started on 2012-09-01. Estimated completion is 2035-05-01.
What conditions does trial NCT01706939 study?
This clinical trial studies the following conditions: Squamous Cell Carcinomas.
What interventions are being tested in trial NCT01706939?
The interventions under investigation include: Carboplatin (DRUG), Standard Dose Radiation (RADIATION), Reduced Dose Radiation (RADIATION).
Who is sponsoring clinical trial NCT01706939?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01706939 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.